At OneMedPlace, our goal is to be your eyes and ears to the biotech and life sciences sector: putting into perspective what we’ve seen so far, and providing you with snapshots of and what’s upcoming.
As Ryan Starkes, Partner and a Practice Leader within BDO’s Technology and Life Sciences Industry Group informs us, BDO is interested in emerging growth life science companies particularly those planning on exploring international development. All companies looking to utilize the capital markets in the U.S., including those in the life sciences industry, have always had to navigate particularly perplexing regulatory requirements.
“Hashtag Biotech” is a new weekly column in which OneMedPlace explores the power of Twitter and other social media tools in facilitating emerging growth company development. This week, we identify the most intriguing biotech investors using Twitter.
OneMedPlace introduces a new series, “The Briefing Room”, capturing the past week’s most important developments in microcap life sciences indexes. This week, we feature Star Scientific, Kips Bay Medical, XOMA and Stellar Pharmaceuticals.
In Part II of our special report on the state of companies operating in central nervous system disease in the public markets, we look at one of the most promising nanocap companies we believe is ready to skyrocket.
Historically, the biotech sector has found it difficult to navigate CNS. It also has affected shareholders in numerous enterprises, with the perception that billions of investor dollars have already been wasted on overreaching and misunderstood technologies.
Defense Advanced Research Projects Agency, or DARPA, has awarded the Company a technology development contract worth up to $3.8 million over five years as part of its Dialysis-Like Therapeutics (DLT) program to treat sepsis, pending satisfactory achievement of key milestones.
IMMUNE Pharmaceuticals is an Israeli and US based emerging leader in the development of antibody therapeutics in cancer and inflammation. IMMUNE has multiple drug candidates based on proprietary cytotoxic formulations, linkers and monoclonal antibodies.
How can one optimally design a clinical trial program for a medical device for a FDA clearance/approval submission? OneMedRadio spoke with Dr. Vladimir Dragalin and Dr. Michael Feldstein of Aptiv Solutions to discuss the changing tides of medical device regulatory and the advantages of using an adaptive design trial.
OneMedForum NY 2012 was well received and the turnout met and exceeded expectations. Unlike the past several years, there is a higher level of optimism within the investment community, according to attendees. The crux of this optimism, of course, is the perceived greater flow of capital to microcap companies that the JOBS Act can provide.
Copyright © 2025 | WordPress Theme by MH Themes